newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and neck cancerRecruitment ongoing for two Phase 1 clinical trials (HB-300 for advanced